<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440504</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-737 ex vivo</org_study_id>
    <nct_id>NCT01440504</nct_id>
  </id_info>
  <brief_title>Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors</brief_title>
  <acronym>ABT737 exvivo</acronym>
  <official_title>Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GRECAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to quantify the ex vivo induction of apoptosis by ABT-737 +
      association platinum in samples exposed and demonstrate the value of this combination
      compared to the agents used alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of apoptotic cells</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>culture ex vivo with exposure to different therapeutic agents alone or in combination.</intervention_name>
    <description>When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient, any chemotherapy naive or ovarian surgery, ovarian cancer with at least five tumor
        samples does not affect the diagnostic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged over 18 years

          -  Ovarian cancer patients with at least five tumor samples does not affect the
             diagnosis, based on other tumor masses

          -  Surgery of any initial chemotherapy naive

          -  Patient information and signed informed consent

        Exclusion Criteria:

          -  A person deprived of liberty or under guardianship

          -  Insufficient tumor samples of ovarian cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOLY Florence, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre françois Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Ovarian</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>BH3-mimetic</keyword>
  <keyword>platin</keyword>
  <keyword>ex-vivo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

